Focus on allogeneic CAR-Ts manufacturing challenges and solutions

Sponsor

While autologous immunotherapies hold a very promising future based on current commercially approved drugs and latest clinical trial results, allogeneic immunotherapies carry the potential to solve some of the scalability obstacles faced by autologous approaches. However, allogeneic approaches come with their own challenges.

Numerous hurdles still remain for allogeneic immunotherapy to address in terms of their commercial viability, including Cost Of Goods (COGs).

During this webinar, we will shed some light on the pitfalls and challenges of allogeneic CAR-T manufacturing and provide a path forward for commercial viability.

Attendees will learn about:

The complexities of manufacturing allogeneic CAR-Ts
Underestimated allogeneic CAR-T manufacturing challenges
What commercially viable allogeneic CAR-T cell therapy manufacturing might look like

Marcos Langtry

Head of Allogeneic Cell Therapy Commercial Development, Lonza Pharma & Biotech

Marcos Langtry is Head of Allogeneic Cell Therapy Commercial Development at Lonza Pharma & Biotech. He is responsible for the allogeneic commercial strategy, current and future offerings, and portfolio optimization. Before joining Lonza, Marcos held several senior level positions at TiGenix, Astra Zeneca and Sanofi in the areas of external manufacturing, process development, technical operations and industrial strategy; where he acquired extensive experience with aseptically filled, biologic and cell therapy products Marcos Langtry holds a Master´s degree in Biochemical Engineering from University College London (UK) and an MBA from Imperial College London (UK). He is also qualified as Chartered Engineer (CEng) and Chartered Scientist (CSci).

Alex Sargent

Research & Development Scientist, Cell & Gene Technologies, Lonza Pharma & Biotech

Alex has been at Lonza for two and a half years. His primary background is in neuroimmunology with a focus on cellular immunotherapies, particularly T-cell based therapies.

Dr Behnam Ahmadian Baghbaderani

Head, Process Development for Cell & Gene Technologies, Lonza Pharma & Biotech

Dr. Baghbaderani is the global head of Process Development, Cell and Gene Technologies at Lonza. He has over 15 years of experience in stem cells engineering, bioprocessing, and cell and gene therapy (C&GT) field. Dr. Baghbaderani holds a PhD degree in Biomedical Engineering from the University of Calgary (Calgary, Canada), where he developed bioreactor protocols for large-scale expansion of human neural stem cells for clinical applications. He completed nearly three years of postdoctoral program including a two-year postdoctoral fellowship at the National Institutes of Health (NIH) / National Institute of Neurological Disorders and Stroke (NINDS). His postdoctoral research at the NIH focused on generation of human induced pluripotent stem cells, bioprocessing of both human embryonic stem cells and human iPSCs and controlled differentiation into neuronal lineage. Since joining Lonza in 2011, he led a group of scientists at Lonza process development team, establishing pluripotent stem cells platform technologies and a cGMP compliant manufacturing process for human induced pluripotent stem cells. Dr. Baghbaderani then led the cell therapy development department (including process development and bioassay services), focusing on the development of cGMP compliant processes and cell characterization assays for different cell therapy applications. As the global head of process development, Dr. Baghbaderani is currently leading the development activities for viral vector and C&GT applications across Lonza Cell and Gene Technologies global network.

Watch now